Method for determining deletions in HBV pre-s2 region

Abstract

A method of detecting pre-S2 deletion mutant LHBS is disclosed herein. The method comprises incubating a biological sample with a first antibody to captured HBS proteins; detecting the LHBS and WT LHBS bound to the immobilized first antibody, respectively; and calculating the amount of the pre-S2 deletion mutant LHBS protein by subtracting the amount of the WT LHBS protein from that of the LHBS protein. Advantageously, by the method described herein, the amount of the pre-S2 deletion mutant LHBS, a potential high-risk marker for HCC incidence in chronic HBV carriers and recurrence in HCC patients after hepatectomy surgery, in a biological sample may be easily calculated without mutual influence between the WT and pre-S mutant LHBS while reducing the labor-intensive process for cloning each gene product before analysis.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application is a divisional of U.S. patent application Ser. No. 14 / 333,346, filed on Jul. 16, 2014, in the United States Patent and Trademark Office, which claims the benefit of U.S. Provisional Application No. 61 / 846,764, filed on Jul. 16, 2013, the disclosure of which is incorporated herein in their entirety by reference.BACKGROUND OF THE INVENTION1. Field of the Invention[0002]The present invention generally relates to a method of detecting pre-S2 deletion mutant large hepatitis B virus surface protein.2. Description of the Related Art[0003]Chronic hepatitis B virus infection is a major cause of hepatocellular carcinoma (HCC) worldwide and its most important cause in Asia. Hepatitis B virus (HBV)-related HCC often occurs at the age of 40 or older, suggesting that HBV may persist in carriers for decades before HCC actually develops. It is important for long-term monitoring high-risk markers in chronic HBV carriers to identify the on...

AI Technical Summary

Benefits of technology

The present invention is a method for detecting a specific mutant protein in a biological sample using an immunoassay kit. This method has the advantage of being able to accurately calculate the amount of the mutant protein without interference from other proteins. It also reduces the time-consuming process of cloning and isolating individual gene products before analysis.

Problems solved by technology

Though up to now the methods (e.g. ultrasound) and tumor markers (e.g. alpha-fetal protein) to diagnose HCC have been established, the high-risk markers for HCC incidence and recurrence have not been fully identified, given that HCC tumorigenesis is a complex process regulated by various crosstalks between host and viral factors.

It was found that the WT and pre-S mutant LHBS often co-exist in one individual HBV carrier, which makes the detection of the pre-S mutant difficult.

Moreover, it requires labor-intensive process for cloning and isolating each individual gene product before the chip analysis.

Images